30.11.2020 • NewsElementis

Elementis Rejects Second Minerals Bid

It took just two hours for the board of UK specialty chemical company Elementis to reject a second takeover bid from Minerals Technologies.

The US specialty minerals firm made a second approach on Nov. 24, raising its all-cash offer to 117 pence per share, up 9% on its initial proposal of 107 pence.

So far, Elementis has declined to enter into discussions with Minerals Technologies, which said it “hopes to engage with the Elementis board with the goal of proceeding to a recommended transaction that is highly attractive to Elementis’ shareholders.”

The New York City-based company is now considering its position, with no certainty that it will make another offer, although any future offer is likely to be solely in cash, it said.

According to UK law, Minerals Technologies has until Dec. 10 to announce whether or not it intends to make a formal offer for Elementis.

Author: Elaine Burridge, Freelance Journalist

It took just two hours for the Elementis board to reject a second takeover bid...
It took just two hours for the Elementis board to reject a second takeover bid from Minerals Technologies. The US specialty minerals firm made a second approach on Nov. 24, raising its all-cash offer to 117 pence per share, up 9% on its initial proposal of 107 pence. (c) Jon Tyson

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.